Jefferies Upgrades Moderna, Citing Optimism Around Promising Experimental Cancer Vaccine
Moderna has a game-changing drug pipeline for 2023, according to Jefferies.
Analyst Michael Yee upgraded Moderna to buy from hold, saying a promising new cancer vaccine from the pharmaceutical company has renewed interest in the stock.
“We upgrade MRNA to BUY on significant new pipeline story and catalysts ahead. The Covid vaccine story is old and numbers came way down already and most investors don’t care much on this anymore. New story is now PCV cancer vaccine opportunity, Phase III RSV data coming up, doublet and triplet virus vaccines in 2023,” Yee wrote in a Monday note.
“We see stock rebounding back up in 2023, a return of pipeline opportunities and a ‘story stock’ as generalist and HC interest revisits the stock,” Yee added.
“We see stock going back up in 2023 on: 1) new PCV cancer story is the “new shiny thing” and a new chapter starting to play out; partner Merck is very excited, will start lots of new studies including adjuvant lung cancer, and PCV could work in many cancers towards a $5-10B+ franchise; MRK and MRNA will run tons of studies where Keytruda works as MRK seeks to bolster PD1 franchise,” Yee wrote.
The analyst’s $275 price target, raised from $170, implies roughly 42% upside from Friday’s closing price. The stock is up 4% in Monday premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Great thanks
yes
Good